80,000 Lung Cancer Patients Walk Into a Lab...

And what comes out might just change how we think about testing for treatable mutations.

Lung cancer isn't one disease. It's more like a dysfunctional family reunion where everyone shares a surname but has wildly different personalities, grudges, and—crucially—weaknesses. Some tumors practically wave flags saying "target me with this drug!" Others play hard to get. A massive new study just catalogued the genetic quirks of over 82,000 lung cancer cases, and the findings are reshaping who should get molecular testing.

The Testing Gap Nobody Talks About

Here's the frustrating reality: we have targeted therapies that work remarkably well for certain genetic mutations in lung cancer. EGFR inhibitors, ALK blockers, drugs targeting KRAS G12C—the arsenal keeps growing. Yet a disturbing number of patients never find out if they'd benefit because their tumors don't get properly tested.

Why? Partly because testing guidelines have historically focused on the "usual suspects"—adenocarcinomas, the most common type. If your lung cancer looks different under the microscope, you might get overlooked. Russo and colleagues decided to challenge that assumption with the largest dataset ever assembled on this question [1].

What 82,328 Tumor Profiles Revealed

The research team analyzed samples processed through comprehensive genomic profiling between 2014 and 2022. Every single case was reviewed by board-certified pathologists—no shortcuts, no assumptions.

The headline number: 35.1% of all cases harbored an actionable genetic alteration. That's more than one in three patients who could potentially benefit from targeted therapy rather than (or alongside) standard chemotherapy.

Adenocarcinomas led the pack at 45.8%, which tracks with what we already knew. But here's where it gets interesting: adenosquamous tumors hit 40.9%. Sarcomatoid carcinomas—those aggressive, weird-looking tumors that often get written off—still showed actionable mutations in 29.1% of cases.

Even squamous cell carcinoma, long considered the "we don't have much for you" histology, produced actionable findings in 6.5% of patients. That sounds small until you remember we're talking about thousands of real people who might have been denied testing under older paradigms [2].

The Sarcomatoid Surprise

The study's most eyebrow-raising finding involves sarcomatoid lung cancers. These tumors have a reputation for being particularly nasty and treatment-resistant. Turns out they're hiding a secret: nearly 10% carry METex14 skipping mutations—four times the rate seen in adenocarcinomas.

METex14 skipping is targetable. Drugs like tepotinib and capmatinib are already FDA-approved for this indication. Imagine being a patient with sarcomatoid lung cancer, hearing your prognosis is grim, and never learning you had a treatable mutation because nobody thought to look [3].

Demographics Matter More Than Expected

The genetic landscape of lung cancer isn't uniform across populations. EGFR mutations showed up far more frequently in patients with East Asian, South Asian, and American genetic ancestry. Women were more likely than men to harbor EGFR mutations and KRAS G12C alterations.

Age played a role too. Younger patients showed higher rates of ALK, RET, and ROS1 rearrangements—genetic changes that respond beautifully to targeted drugs. The researchers found statistically significant correlations between age and several mutation types, reinforcing that no demographic should be automatically excluded from testing [4].

The High TMB Plot Twist

Tumor mutation burden (TMB)—the total number of mutations a cancer carries—has become important for predicting immunotherapy response. High TMB generally means more abnormal proteins for the immune system to recognize.

Here's the twist: patients with targetable driver mutations typically had low TMB. Only about 19% of those with actionable alterations showed TMB ≥10 mutations per megabase. This matters because it suggests these two treatment strategies—targeted therapy and immunotherapy—often apply to different patient populations. Knowing which lane your tumor belongs in requires testing [5].

The Bottom Line

This study delivers a clear message: universal molecular testing for all lung cancer subtypes isn't just nice to have—it's a matter of equity. When we selectively test based on histology or demographics, we inevitably leave patients behind.

The data supports testing everyone. A third of lung cancer patients carry mutations we can target. The only way to find them is to look.

References

1. Russo A, Javey M, Huang RSP, et al. Molecular Profiling across 80,000 Patients with Lung Cancer. J Thorac Oncol. 2026. DOI: 10.1016/j.jtho.2026.103695. PMID: 41903702.

2. Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495-509. DOI: 10.1038/s41568-019-0179-8. PMID: 31406302.

3. Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47-51. DOI: 10.1038/s41591-019-0716-8. PMID: 31932802.

4. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911. PMCID: PMC4633915.

5. Singal G, Miller PG, Agarwala V, et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. JAMA. 2019;321(14):1391-1399. DOI: 10.1001/jama.2019.3241. PMID: 30964529.

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.